Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
08/2005
08/09/2005US6926938 Hardshell gelatin capsule reducing the static electricity and enhancing the lubrication of film
08/09/2005US6926916 Chewing gum compositions
08/09/2005US6926913 Tetraglycol as a solvent for molecular iodine in the preparation of a topical counter-irritant against skin burns
08/09/2005US6926911 administering a sodium channel blocker to an airway surface in a vehicle comprising potassium sulfate or potassium phosphate as an ionic osmolyte to increase the volume of liquid on the airway surface, for cystic fibrosis
08/09/2005US6926910 Hydrophobe biomolecular structure
08/09/2005US6926909 Chrono delivery formulations and method of use thereof
08/09/2005US6926908 Formulation for inhalation
08/09/2005US6926907 Pharmaceutical compositions for the coordinated delivery of NSAIDs
08/09/2005US6926906 Active pharmaceutical ingredient, especially pseudoephedrine hydrochloride, embedded into an oily matrix; viscosity imparting agents; surfactant; suspending agent; and suspension medium.
08/09/2005US6926905 Liposomak compositions and methods of preparation
08/09/2005US6926888 producer cell ( encapsulated in a matrix which containing alginates) containing a plasmid that includes a nucleic acid sequence that encodes endostatin, angiostatin, thrombospondin, or prolactin
08/09/2005US6926178 Valve with a two-component seal
08/09/2005CA2303828C Chewing gum containing physiological cooling agents
08/09/2005CA2278785C Process for preparing solid pharmaceutical dosage forms
08/09/2005CA2276445C Transdermal hormone-delivering therapeutic system
08/09/2005CA2182508C Abuse resistant tablets
08/09/2005CA2178603C Transdermal therapeutical system for preventing poisoning by organophosphoric neurotoxins that consists of a combination of active substances including a parasympathomimetric and a parasympatholytic agent
08/09/2005CA2168012C Polymeric matrices and their uses in pharmaceutical compositions
08/09/2005CA2103961C Compositions which contain active substances and are in the form of solid particles
08/09/2005CA2019676C Particle-mediated transformation of animal somatic cells
08/04/2005WO2005071082A1 Antisense oligonucleotide having anticancerous activity
08/04/2005WO2005071071A1 Ptd-human choline acetyltransferase fusion protein and its application
08/04/2005WO2005071067A2 Non-animal origin stabilizers and processes for producing the same
08/04/2005WO2005070952A1 Lipid- derivatized bisphosphonic acid
08/04/2005WO2005070467A2 Method of protecting sensitive molecules from a photopolymerizing environment
08/04/2005WO2005070466A2 Liposome composition for delivery of therapeutic agents
08/04/2005WO2005070465A2 Lipid-based dispersions useful for drug delivery
08/04/2005WO2005070464A2 A tablet formulation of clopidogrel bisulphate
08/04/2005WO2005070451A1 Pharmaceutical composition comprising non-glycosylated erythropoietin
08/04/2005WO2005070444A2 Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
08/04/2005WO2005070425A1 Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same
08/04/2005WO2005070417A1 Compression coated tablet comprising sumatriptan
08/04/2005WO2005070401A1 Encapsulation of lipid-based formulations in enteric polymers
08/04/2005WO2005070400A1 Methods and compositions for imaging
08/04/2005WO2005070399A1 Microemulsions for pharmaceutical compositions
08/04/2005WO2005070398A2 Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
08/04/2005WO2005070397A1 Method of preparing low-crystallinity oltipraz or amorphous oltipraz
08/04/2005WO2005070396A1 Pharmaceutical formulations comprising metformin and a fibrate, and processes for obtaining them
08/04/2005WO2005070395A1 Support accumulating in injured part in vascular channel
08/04/2005WO2005070394A2 Ternary non-lamellar lipid compositions
08/04/2005WO2005070393A2 Directly compressible pharmaceutical composition of the rapamycin ester cci-779
08/04/2005WO2005070392A2 Non-lamellar compositions of dioleoyl phosphatidylethanolamine and polysorbate 80
08/04/2005WO2005070391A2 Method of producing microparticles
08/04/2005WO2005070390A2 Mitratapide oral solution
08/04/2005WO2005070367A1 Solid dosage form
08/04/2005WO2005070333A1 Drug delivery to a joint
08/04/2005WO2005070332A1 Long-term delivery formulations and methods of use thereof
08/04/2005WO2005070134A2 Iontophoretic devices and methods
08/04/2005WO2005070003A2 Abuse potential reduction in abusable substance dosage form
08/04/2005WO2005058284A3 Fast-disintegrating tablets
08/04/2005WO2005053652A8 Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
08/04/2005WO2005053605A3 Therapeutic liposomes
08/04/2005WO2005051305A3 Enhanced drug delivery
08/04/2005WO2005048930A3 Surfactant-based gel as an injectable, sustained drug delivery vehicle
08/04/2005WO2005041936A3 Methods of treatment of cancer using a composition comprising a cytotoxic drug and a porous carrier material
08/04/2005WO2005034919B1 Method of producing dosage units of a solid drug form containing warfarin sodium salt as active component
08/04/2005WO2005023175A3 Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound
08/04/2005WO2005009322A3 Delivery system for topical medications
08/04/2005WO2005007129A3 Topical formulations with bioactive components
08/04/2005WO2005004919A8 Extended release systems for macrolide antibiotics
08/04/2005WO2004108072A3 Delivery of immune response modifier compounds using metal-containing particulate support materials
08/04/2005WO2004046165A3 Treatment of ophthalmic conditions with kpv and kpv dimers
08/04/2005US20050171513 External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
08/04/2005US20050171512 Devices, systems and methods for patient infusion
08/04/2005US20050171501 Intravenous solution producing systems and methods
08/04/2005US20050171464 Method and device for transdermal electrotransport delivery of fentanyl and sufentanil
08/04/2005US20050171203 includes water, at least one preservative, at least one taste-masking agent, and an optional viscosity control agent; suitable for oral administration
08/04/2005US20050171200 Use of EPA and DHA in secondary prevention
08/04/2005US20050171193 Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
08/04/2005US20050171177 Method of treatment of Candida isolates
08/04/2005US20050171127 Epzicom; coated tablet formulated with Ceolus" microcrystalline cellulose for once daily administration; synergistic HIV treatment
08/04/2005US20050171119 Two-layer tablet of efletirizine (2-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid) containing an immediate release layer and a time-release layer for once daily dosage; antihistamine, bronchodilator and antispasmodic agent
08/04/2005US20050171083 Modified release pharmaceutical formulation
08/04/2005US20050171077 Compositions containing piperacillin and tazobactam
08/04/2005US20050171070 Stable salts of o-acetylsalicylic acid containing basic amino acids II
08/04/2005US20050171047 Immunostimulatory nucleic acid molecules
08/04/2005US20050171021 Buffered drug formulations for transdermal
08/04/2005US20050171009 by addition of surfactants such as nonionic surfactants of the (poly)ethoxylated fatty acid type; storage stability to hydrophobic aggregation nuclei for several months under temperature stress
08/04/2005US20050171001 Hemostatic compositions and devices
08/04/2005US20050170988 Water; an oil phase, which contains hydrophobic oil and optionally dissolved lipophilic materials, and an emulsifier mixture of an ethoxylated (hydrogenated) castor oil and an emulsifier with a given NRU50 value; storage stability, clarity; eye compatibility
08/04/2005US20050170553 Apparatus for controlled alignment of catalytically grown nanostructures
08/04/2005US20050170509 Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
08/04/2005US20050170508 For transfecting nucleic acids in vivo or ex vivo; vesicle forming lipid and hydrophilic polymer; gene therapy
08/04/2005US20050170365 Nucleotide sequences coding modified deoxyribonuclease for treatment of pulmonary, autoimmune and/or cystic fibrosis
08/04/2005US20050170014 Carbonyl iron pharmaceutical dosage forms for the treatment of iron-deficiency anemia
08/04/2005US20050170009 Traditional chinese pharmaceutical formulation for treatment of paradentosis, process for preparation and use thereof
08/04/2005US20050170007 Ude of a mare's milk concentrate dried on a highly-dispersed, biologically inert matrix
08/04/2005US20050170005 Methods for encapsulating small spherical particles prepared by controlled phase separation
08/04/2005US20050170004 electrostatically attaching the peptide, polysaccharide, or a glycoprotein to a nanoparticle (organic wax) prior to the oral ingestion, to inhibit enzymatic degradation of the peptide, the polysaccharide, or the glycoprotein upon oral ingestion
08/04/2005US20050170003 amlodipine maleate, ethylcellulose, mannitol, or corn starch as a carrier, maleic acid, phosphoric acid sorbic acid or ascorbic acid as an acid to prevent the formation of N-(2-{[4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydro-2-pyridyl]methoxy}ethyl)aspartic acid
08/04/2005US20050170002 dissolving a first quantity itraconazole in the water-miscible first organic solvent to form a first solution; mixing first solution with a second solvent to precipitate itraconazle, seeding the first solution or the second solvent or pre-suspension
08/04/2005US20050170001 polyundecanolactam or polylaurolactam polyamide and 0.2 to 3% of a soluble ceramic in which silver ions are encapsulated; encapsulation protects silver ion from ultraviolet radiation and temperature; electrostatic powder coating or by fluidized-bed dip coating
08/04/2005US20050170000 Particulate materials
08/04/2005US20050169999 beta -carotene was dissolved in n-isobutyl or isobutyl acetate, hot solvent phase was dispersed in a modified water starch solution, evaporation of solvent, drying the dispersion; obtained beta -carotene used as colorant, for food, beverages, nutrition fortified food and pharmaceuticals
08/04/2005US20050169997 Loading water insoluble drugs ( Nelfinavir, midazolam or indomethacin) or nicotine as water soluble drug onto ion exchange acrylic resins using water or a water miscible or water-immiscible solvent; efficient, environmentally friendly (less cosolvent); changes in release rate of drugs, taste masking
08/04/2005US20050169996 Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
08/04/2005US20050169995 Modulation of gastrointestinal epithelium proliferation through the Wnt signaling pathway
08/04/2005US20050169994 Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
08/04/2005US20050169993 Sustained-release formulation
08/04/2005US20050169992 Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
1 ... 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 ... 2991